I
n healthy individuals without diabetes, excursions in diurnal plasma glucose concentrations are usually confined within narrow limits, 50 to 160 mg/dl, despite marked variations in nutrient availability and patterns of fuel utilization. The remarkable ability to maintain glucose concentrations within these narrow limits is due to a complex interplay among a variety of homeostatic regulatory factors and mechanisms, which have yet to be defined in detail. However, paramount among these regulatory factors is the minute-to-minute, feedback regulated, release of insulin into the portal circulation, its prompt effect on the liver and other responsive tissues, and its rapid clearance from plasma.
In the insulin-requiring diabetic patient, regardless of the type of insulin injected subcutaneously, it has been difficult to replicate the normal diurnal patterns of free insulin concentrations seen in the nondiabetic patient's portal or peripheral venous circulation. Indeed, after the initial development and use of short-acting preparations of insulin, the trend, worldwide, was to use longeracting forms of insulin. Although the development of these new preparations of insulin was considered a major, practical advance, it made the task of replicating normal patterns of insulinemia even more unlikely than when insulin had to be given as a short-acting preparation three or four times a day. In view of the inability to reproduce the variable diurnal concentrations of the primary hormone that regulates nutrient utilization and fuel mobilization, the failure to normalize diurnal glucose concentrations was not surprising. The comparatively sluggish ebbs and tides in insulinemia produced with subcutaneous insulin resulted in several predictable patterns: First, if insulin concentrations in blood did not rise from fasted-to fed-state levels immediately after a meal, postprandial glucose concentrations were seldom maintained below 160 mg/dl. Second, efforts to normalize postprandial plasma glucose levels with more insulin almost invariably resulted in postprandial or nocturnal hypoglycemia because mobilization of insulin from subcutaneous insulin depots and from circulating antibodies was not under feedback control and could not be halted abruptly. While symptomatic hypoglycemia was an immediately discernible and sometimes life-threatening complication, moderate postprandial hyperglycemia was usually silent clinically and carried only a long-range, somewhat theoretic risk. Clinical strategies directed at achieving good glucose control were limited by a desire to avoid episodes of severe hypoglycemia. This resulted in elevated mean diurnal plasma glucose concentrations and an abnormally wide amplitude of diurnal glycemic excursions in which the nadir was maintained above 40-50 mg/dl.
Many of the long-term complications seen in insulinrequiring diabetic patients are not averted by conventional modes of insulin therapy. A commonly expressed hypothesis is that more intensive efforts at improved metabolic control in diabetic subjects may result in decreased long-term complications. Although data supporting this hypothesis come, primarily, from uncontrolled, retrospective clinical studies and animal models for diabetes, increasing attention is being devoted to development of strategies designed to achieve improved blood glucose and metabolic control in insulin-dependent diabetic patients. These highly varied approaches can be divided, arbitrarily, into three categories (Table 1) : transplantation, mechanical devices, and modifications of conventional techniques. The transplantation approach seeks to restore normal metabolic function to the diabetic patient by replacing functionally normal islets or beta cells. The other techniques seek to restore normal metabolic function by replacing deficient insulin secretion with exogenous insulin.
TRANSPLANTATION APPROACH
The status of techniques for transplantation of the intact pancreas, isolated islets of Langerhans, or isolated 1 ' 2 A number of laboratories are attempting to solve the problems that make transplantation less practical than conventional insulin therapy for the management of human diabetes, e.g., tissue procurement, isolation and harvesting of islets or beta cells free of exocrine tissue, immunologic rejection. This approach will not be discussed further here.
MECHANICAL DEVICE APPROACH -OPEN LOOPS AND CLOSED LOOPS
T he mechanical device approach involves the use of pumps that infuse insulin into the blood, skin, peritoneal cavity, or other tissues. Using continuous infusions, normal diurnal patterns of insulinemia could be imitated more closely than by injecting currently available forms of insulin subcutaneously or intramuscularly. Some of these devices function as closed loops insofar as they infuse insulin under feedback control of the continuously monitored glucose concentration. Others operate as open loops since the infusion of insulin is preplanned, and modified in a nonautomated manner by intermittent, conventional, glucose measurements. Although both techniques infuse insulin according to predetermined plans (algorithms), the open loop systems more clearly resemble conventional insulin therapy, insofar as there is no feedback regulation of insulin based on the continuously monitored glucose concentration.
With open loop systems, insulin can be delivered rapidly to the blood stream at the start of a meal, for empirically determined durations, so as to blunt postprandial hyperglycemia. After meals, this high rate of insulin delivery can be lowered abruptly and returned to a basal rate so as to avoid postprandial hypoglycemia. This type of insulin delivery has been termed square wave delivery. As with conventional insulin therapy, avoiding fasting and postprandial hypoglycemia is a key goal for these systems.
Closed loop devices consist of three components: a glucose sensor, a computer-controller, and an insulin pump. Because the only glucose sensors that have the reliability required for continuous monitoring in humans are too large for implantation, all closed loop systems currently available are bulky, bedside devices. A number of these devices have been developed. The Biostator system developed by Clemens' group at Miles Laboratories, Elkhart, Indiana, is being used by a number of North American and European investigators. Although early studies of these bedside devices by Albisser and his colleagues in Toronto show postprandial hypoglycemia, this problem has been resolved partially by these and other investigators by improvements in the algorithms for insulin delivery and provision for a glucose and/or glucagon infusion capacity to avert hypoglycemia. These devices are now capable of achieving normal diurnal glucose concentrations in insulin-dependent diabetic patients for periods up to several days. None of these devices permit blood glucose control in ambulatory diabetic patients. The characteristics and clinical research applications of closed loop systems have been reviewed recently. 3 ' 4 Open loop devices are simple, consisting of pumps that do not require glucose sensors or computer-controllers for insulin delivery. These devices can be small and permit long-term, portable use in ambulatory diabetic patients by means of battery power. Most open loop devices permit insulin delivery at variable speeds in a square wave pattern. Thus, appropriate low rates of infusion can be selected that will meet basal requirements for individual patients while higher rates can be chosen to meet the insulin requirements of carefully planned meals. A number of pumps are available for potential use as open loop delivery systems. Dr. Elsa Paulsen used a portable infusion pump, developed by the Alza Corporation of Palo Alto, California, for long-term intravenous insulin delivery to a patient with resistance to subcutaneously injected insulin. 3 We have used a portable pump, developed by the Auto Syringe Corporation of Farmingdale, New York, for intravenous insulin delivery in ambulatory diabetic patients for periods up to several months. Other portable insulin infusion pumps have been developed by the Siemens Corporation of West Germany 6 and Michael Albisser's group at Toronto. 7 Additional pumps are under development in collaboration with investigators at the Mayo Clinic, the University of Minnesota, and in England under a contract from the National Institutes of Health. All of these pumps are designed for extracorporeal, portable use.
One open loop device has been developed for use as an implantable pump. The Infusaid pump, developed by the Metal Bellows Corporation of Sharon, Massachusetts, is an 8 X 3-cm disk which has been implanted in dogs for long-term heparin infusions. A modified version, which can be switched from a low to a higher infusion rate, has been used recently to infuse insulin in diabetic dogs. There is no published evidence that these two-speed pumps normalize glycemic patterns reliably or that they are a significant improvement over subcutaneous insulin delivery in diabetic dogs. 8 The programs for open loop systems can be developed in a variety of ways. Slama and associates determined total daily insulin requirements using subcutaneous insulin, and gave 60% of this total as intravenous insulin infusions during meals.** The remainder was given at a constant, low, infusion rate chosen to stimulate basal insulin requirements. Genuth and Martin calculated basal insulin requirements by means of overnight, intravenous insulin infusions. 10 Then, with the help of a computer, they calculated diurnal insulin infusion rates as a function of basal requirements. Service has reported some success in open loop insulin delivery with a readily available infusion pump. 11 Irsigler and associates in Vienna 12 have determined diurnal insulin requirements with bedside closed loop devices and used this information to program portable open loop devices developed by the Siemens Corporation.
Regardless of the method used to calculate an individual's open loop insulin requirements, highly motivated volunteers are required, preferably in a controlled research environment. These subjects must follow a regimen involving a preplanned dietary, exercise, and glucose monitoring schedule, and appropriate responses to hypoglycemia. Because of the difficulty in finding many adult and adolescent diabetic patients to follow rigorously protocols involving frequent urine testing, a well-defined diet, and two or three injections of insulin per day, open loop systems now available may have a limited application in routine clinical practice at the present time. The emotional impact of these devices in children remains to be studied. The art and science of motivating and educating diabetic patients to accept an added burden and inconvenience to improve their blood glucose control is a complicated process. An understanding of the dynamics of this process will come from physicians, psychologists, educators, and sociologists, not from engineers, physiologists, or biochemists. As the diabetic patient's self-care becomes more demanding and complicated, physical and behavioral scientists should devote their skills to defining and evaluating these clinical strategies in a real-life setting. These strategies are under study in several centers.
Of equal concern now are the theoretic and practical hazards demonstrated in preliminary feasibility studies involving open loop devices. For example, in Slama's early studies, nadir blood glucose concentrations of 30, 31, and 38 mg/dl were observed in three juvenileonset diabetic patients while glycemic nadirs of 18, 23, 30, and 32 mg/dl were observed in four 36-68-yr-old volunteers with onset of diabetes after age 35. On the other hand, in the studies of Genuth and Martin, hypoglycemia was neither as common nor as severe. As they point out, however, many of their patients were obese, with maturity-onset diabetes. It may be easier for maturity-onset diabetic patients, because of their own residual endogenous insulin secretory capacity, to control their diabetes than for juvenile-onset diabetic patients. Furthermore, obese, hyperinsulinemic diabetic patients may have a reduced risk of developing postprandial and fasting hypoglycemia because they are less sensitive to mild degrees of overinsulinization. This resistance to overinsulinization may be present also in many pregnant diabetic patients. As noted by Genuth and Martin, hypoglycemic reactions were common when their approach was used in juvenile-onset type diabetic patients who, presumably because of both limited endogenous insulin secretory capacity and sensitivity to insulin.
Additional hazards in the use of open loop devices are the risks of phlebitis, infection, and the occlusion or extravasation of infusion lines. Inactivation of insulin within the pumps or tubings used in open loop systems when concentrated insulin solutions are used for prolonged periods is an additional problem. Our experience at Washington University has been that a change in small metal needles is required every 3-4 days to avert phlebitis. Use of a Broviac silastic catheter, tunneled under the skin before insertion into a large vein to reduce infection risks, has been associated with severe bacteremia in at least one diabetic subject. Until the safety of open loop systems for tight glucose control by means of intravenous insulin delivery is established in carefully defined groups of diabetic patients, their use should be limited to clinical research environments. Routine clinical use of these devices outside a research setting by personnel unfamiliar with their use would seem unwarranted now.
Pickup and associates in England have employed a small pump to infuse insulin continuously into subcutaneous tissues. 13 This approach has the theoretic advantage of reducing the risk of phlebitis. However, subcutaneous injections may not reproduce the postprandial pattern of rapid increments in plasma insulin levels seen in nondiabetic or in diabetic patients given intravenous insulin infusions. Eaton's group at the University of New Mexico has infused insulin intraperitoneally and demonstrated rapid absorption of insulin into the systemic circulation of a patient undergoing peritoneal dialysis. The kinetics of insulin absorption from muscle may be more rapid than subcutaneous injection and may offer yet another alternative to intravenous injections. A number of centers are exploring actively both the continuous subcutaneous and intraperitoneal techniques as alternatives to intravenous insulin delivery. Recently, Tamborlane and associates at Yale have reported superb blood glucose control (mean plasma glucose 95 mg/dl) in seven diabetic children treated with continuous sub-cutaneous insulin delivery.
14 In these subjects a single insulin bolus was given subcutaneously 30 min before meals. No episodes of hypoglycemia were encountered in these studies. These investigators have now extended these studies to 2 wk in some patients.
INTENSIVE, CONVENTIONAL APPROACHES
A third approach for achieving improved metabolic control in insulin-dependent diabetic patients uses modifications of traditional therapeutic techniques. These approaches use multiple injections of short-acting insulin, in combination with preplanned diet and exercise, and frequent blood rather than urine glucose monitoring. Examples of specific modifications of conventional insulin therapy that could be used to simulate, more closely, normal plasma insulin profiles and, theoretically, improve metabolic control in insulin-dependent diabetic patients are listed in Table 2 . Although readily formulated, implementation of these changes requires considerable motivation and some skill on the part of the patients and their therapists.
All diabetologists are aware of at least a few highly motivated patients, some of them physicians or nurses, who have evolved their own algorithms for glucose control with three or more insulin injections per day. Using regimens that include empirically derived diets, programs for physical activity, and well-defined modes of averting and coping with hypoglycemia, these patients seem to be aglycosuric most of the day and often have plasma glucose measurements within a near normal range. Recently, some of these well-controlled patients achieved normal hemoglobin Ale concentrations in blood. 15 Since a number of centers have found that significant residual insulin secretory capacity facilitates greatly tight blood glucose control, 16 ' 17 it would seem imperative that the insulin secretory capacity be defined carefully in all future studies purporting to demonstrate tight or improved glucose control. The availability of urine and plasma C-peptide and plasma free insulin assays should make this definition possible in most diabetic patients.
Some of the earliest applications of continuous blood glucose monitoring were by Molnar and associates at the Mayo Clinic. 18 Using subcutaneous insulin injections, these investigators were unable to achieve anything approximating normal metabolic control in their group of extremely "unstable" juvenile-onset type diabetic patients despite the availability of a research center using continuous glucose monitoring, carefully controlled diet and exercise protocols, and multiple insulin injections per day. These discouraging results, obtained in a near optimal research setting, have been used to support the view that, in certain "unstable" diabetic patients, any semblance of normalization of meta- The failure of the Mayo Clinic group and others to normalize diurnal glucose concentrations in some juvenileonset type diabetic patients can be interpreted in a number of ways. First, the Mayo experience may be applicable only to that small minority of extremely "brittle" diabetic patients with little or no insulin secretory reserve or deficiency in compensatory glucoregulatory responses to hypoglycemia. 20 Research centers attract these difficult to manage diabetic patients.
Second, it is possible that Molnar's clinical strategies were inadequate in regards to the timing or type or amount of insulin or diet given. Third, it is possible that those advocating tight control would be dismayed both by the postprandial hyperglycemia and the postexercise, between-meal or nocturnal hypoglycemia that occurs even in asymptomatic patients when glucose concentrations are measured frequently or continuously. Fourth, it could be argued that the key to optimal diabetic control is not the strategy or zeal of the therapist but the patient and the characteristics of his/her diabetes. Given an exceptionally motivated, reliable, and resourceful diabetic patient, who is willing and able to make a personal commitment to tight controj, almost any diabetologist could achieve improved metabolic control over that seen in patients not possessing these characteristics.
Furthermore, as stated above, there is now growing evidence that the ability to achieve optimal metabolic control may be dependent, in part, on the degree of endogenous insulin secretory reserve and/or on the sensitivity to mild or moderate degrees of hyperinsulinemia. 16 ' 17 ' 21 Sacca and Liljenquist and their associates at Yale, Vanderbilt, and Washington University have elucidated recently some of the glucoregulatory functions of the liver under a variety of conditions. 22 " 24 As glucose concentrations increase or decline, hepatic glucose release seems to decrease or increase reciprocally and glucose concentrations tend, therefore, to be maintained within a physiologic range. These changes in hepatic glucose release seem to be partially independent of measurable changes in the plasma concentrations of known glucose counterregulatory hormones. As demonstrated previously by Campbell, if normal individuals are made moderately hyperinsulinemic their plasma glucose concentrations decline but then plateau before reaching frankly hypoglycemic levels. The mechanisms for these autoregulatory events are not yet known fully, but it is possible that they may be defective in certain diabetic patients in whom, unlike normal subjects, moderate hyperinsulinemia produces overt hypoglycemia. 21 Such individuals iaaight not respond favorably to intensive efforts directed at tight metabolic control, regardless of the specific approach used. Whether these individuals represent a significant proportion of insulin-dependent diabetic patients or diabetic patients with a selective form of autonomic neuropathy, as suggested by Campbell, remains to be determined.
COMPARISONS BETWEEN MECHANICAL AND CONVENTIONAL APPROACHES
Many of the questions raised in discussions of the effectiveness or applicability of any intensive efforts at metabolic control will probably not be resolved in the near future. However, it does not seem unreasonable to ask whether most of the patients willing to assume the added responsibilities associated with open loop techniques might not also respond favorably to intensive, conventional therapy using some of the techniques outlined in Table 2 .
There is some reason to suspect that intensive efforts at metabolic control in certain insulin-dependent diabetic patients, treated with conventional modes of therapy, may result in mean diurnal glucose concentrations that are similar or comparable to those achieved with open loop insulin delivery. For example, Slama's early patients had mean fasting and postprandial blood glucoses of 86 and 94 mg/dl, respectively, with subcutaneous insulin and mean diurnal blood glucoses of 92 mg/dl with open loop infusions. In our group's experience with pregnant diabetic women, mean diurnal glucose concentrations were 88-134 mg/dl, with conventional therapy given by a skilled obstetrician, and 82-117 mg/dl, with a closed loop system. 25 Thus, in the pregnant diabetic patient, even a closed loop system may produce only a small decrement in mean diurnal glucose levels in comparison with intensive conventional therapy. A key advantage of the currently available, cumbersome, bedside, closed loop devices is that they achieve normalization of the amplitude of glycemic excursions and mean diurnal glucose concentration while avoiding hypoglycemia or the need for repeated studies to determine each patient's optimal insulin infusion rates. As pointed out by Horwitz et al., 26 even closed loop devices may result in elevated free insulin levels in peripheral venous plasma. The practical significance of this observation will require further study since chronic hyperinsulinemia could have significant metabolic effects.
The investigator interested in comparing the efficacy of a new technique, such as an open loop system, with a control method using intensive conventional therapy is faced with a difficult task. Such a study could be so subject to bias, such as in patient selection, that interpretation of the data would be impossible. One approach is to use an independent team of experienced personnel who are avid advocates of conventional forms of therapy, and then to compare the results of their efforts with those obtained in these same patients in a crossover study using the new approach under study. In this experimental design, neither group influences the outcome of the other's approach except that both try their best to demonstrate the relative merits of their respective techniques.
An alternative approach is to compare the new techniques, whether a mechanical device or an intensive, conventional protocol, to the results observed in a control group of nondiabetic subjects. Although this is a much more rigorous test of the efficacy of a new methodology, it is perhaps performed more easily by most investigators and obviates the problems associated with a comparison of two different techniques by two independent groups of investigators. To date, studies of this type have been conducted only with cumbersome closed loop devices and have been centered, primarily, on blood glucose measurements. Further studies of the short-term effect of normalization or near normalization of diurnal blood glucose concentrations with exogenous insulin delivery on carbohydrate, fat, and protein homeostasis are underway currently in a number of research centers.
Since closed loop devices can be expected to achieve normal metabolic patterns for short-term studies only, intensive conventional and, possibly, open loop approaches will be required to test the effect of significantly improved metabolic control in longer-term studies. The primary purpose for developing methods for improved glucose control for prolonged periods is to study the specific effect of these therapeutic interventions on the long-term complications of diabetes and their ultimate effect on the quality and duration of these patients' lives. In a sense, these new techniques and clinical strategies are needed to test the hypothesis that efforts directed at improved metabolic control, beyond that which is achieved currently with conventional treatment, may be beneficial. Although breakthroughs in technology are to be expected, the answer to these fundamental questions will not be available for some time.
In this issue of DIABETES CARE, Slama and associates at the Hotel-Dieu Hospital in Paris report on their study of insulin absorption kinetics with a portable open loop system. In this study they infused insulin subcutaneously in four men with recently diagnosed, symptomatic diabetes. After an 11-fold step-up from a basal insulin infusion rate, mean plasma insulin concentrations peaked at 87-125 min after the onset of the 20-30-min square wave infusion. Plasma insulin concentrations remained above basal levels for at least 3-4 h after discontinuation of the higher infusion rate. As the authors note, this pattern was similar to that seen after administering a bolus of insulin subcutaneously. Because the kinetics of insulin absorption are similar to that of conventional insulin therapy, the authors suggest, as have others, that the higher insulin infusion rate be started at least 30 min before meals. This has been done, with apparent success, by the Yale group.
In their report, Slama et al. make no attempt to study the feasibility of achieving optimal blood glucose or metabolic control. It is noteworthy that in the three patients on whom data is provided, plasma glucoses peaked at 160-280 mg/dl after meals. In the patient with the best plasma glucose control (patient 4) plasma C-peptide concentrations increased approximately fourfold in response to meals. In a patient for whom no plasma glucose values are reported, plasma insulin levels increased unexplainedly from 18 to 55 /u-U/ml at a time when there was no step-up in the insulin infusion rate but plasma C-peptide levels increased two-to threefold. In the two patients in whom plasma C-peptide levels showed the least increment after meals (patients 2 and 3), plasma glucose concentrations were highest after meals and showed the greatest glycemic excursions (nadir concentrations less than 50 mg/dl in patient 2 and 60 mg/dl in patient 3). Clearly, any attempt to minimize postprandial hyperglycemia in these subjectcs by infusing more insulin could have resulted in a greater risk for developing postprandial hypoglycemia.
These results serve to emphasize what was discussed previously in regards to conventional therapy, i.e. glucose control is most difficult in patients with the least insulin secretory reserve and efforts to normalize postprandial glucoses often lead to hypoglycemia. The authors' speculation that timing of insulin delivery may improve their results and a comparative, crossover study using conventional therapy may prove of great interest. Taken together, the initial studies of Pickup, Slama, Tamborlane, and others suggest that continuous subcutaneous insulin infusions may produce less hypoglycemia than open loop intravenous insulin delivery while eliminating much of the postprandial hyperglycemia seen with conventional insulin therapy. The relative merits and potential applications of the intravenous and continuous subcutaneous insulin treatment regimens require further clinical study. Since the equipment for these open loop methods is available already, numerous studies can be expected in this area in the near future.
In another report in this issue of DIABETES CARE, Lambert and his associates at the University of Louvaine in Brussels report their experience in the use of a bedside closed loop device, developed by their group, as a tool to determine subcutaneous insulin requirements in insulin-dependent diabetic patients. They first determined the insulin delivered by their device to achieve normal glucose levels in 11 subjects with diabetes for at least 3 yr with age at onset of diabetes under 25 in 10 of 11 subjects. Using information obtained during closed loop control, these investigators proceeded to partition daily insulin requirements so that insulin could be administered as two subcutaneous injections of a mixture of short-and intermediate-acting insulin per day. Using this approach, they were able to reduce the M value (an index of mean blood sugar control proposed by Schlichtkrull) while not affecting the amplitude of glycemic excursions (a measure of diabetic instability proposed by Service). Specific modifications of conventional therapy resulting from these studies included giving more insulin (0.9-1.2 U/kg body wt) and giving a higher proportion of the total as short-acting insulin (37-56% of total insulin given per day). The reported improvement in glucose control is not compared to efforts without the use of a closed loop system so that it is conceivable that similar improvements could have been obtained with more conventional techniques. A key advantage, however, is that the new regimens were developed after a single 24-h study period and seemed to suit the individual needs of patients with varying insulin requirements. As pointed out by the authors, translating closed loop insulin requirements to programs for subcutaneous insulin therapy requires some experience, and an empiric, individual approach to avert nocturnal hypoglycemia. The reasons for nocturnal hypoglycemia are not clear from this study but confirm the observations of others that greater amounts of short-acting insulin are required to achieve euglycemia after breakfast than after an evening meal. Further studies will be needed to define the dietary, exercise, and glucose-monitoring regimentation required of these subjects, as well as the effect of specific therapeutic interventions on long-term hemoglobin Ale measurements. The frequency at which patients have to be rehospitalized for reprogramming will also have to be studied. Since a number of centers are using closed loop devices as a tool to help determine subcutaneous insulin therapy, more should be learned quickly concerning the efficacy and limitations of this approach.
SUMMARY
T he realization that many of the long-term complications of diabetes are not averted with currently practiced therapy has prompted renewed interest in the development of improved methods for blood glucose and metabolic control in diabetic patients. Of the numerous approaches available, the transplantation approach offers great promise despite numerous obstacles related to technology and immune rejection. 27 The closed loop mechanical device approach is in urgent need of a reliable miniature glucose sensor. Large, bedside, closed loop devices are available currently that can normalize glucose concentrations for several days and are powerful tools for metabolic research. There is growing interest in portable open loop insulin infusion pumps which may enable significantly improved blood glucose and metabolic control for prolonged periods in many insulindependent diabetic patients. There has been renewed interest in strategies for improved metabolic control in diabetes by modifications of conventional programs for insulin injection and dietary management. There is a growing trend to place an increasing burden of responsibility for glucose monitoring and self-care on welltrained and motivated diabetic subjects for purposes of achieving improved metabolic control. It is hoped that these varied approaches can be used soon to test the hypothesis that specific therapeutic interventions will improve significantly both the quality and duration of the life of diabetic patients.
e Spectrum of Insulin Resistance
